BrainsWay Ltd. (NASDAQ:BWAY) Short Interest Up 68.0% in January

BrainsWay Ltd. (NASDAQ:BWAY) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 63,000 shares, a growth of 68.0% from the January 15th total of 37,500 shares. Based on an average daily trading volume, of 67,300 shares, the short-interest ratio is presently 0.9 days.

Institutional Trading of BrainsWay

Institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. increased its stake in shares of BrainsWay by 316.3% during the third quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock valued at $136,000 after purchasing an additional 11,221 shares in the last quarter. Sei Investments Co. purchased a new stake in BrainsWay in the fourth quarter worth approximately $149,000. Rhumbline Advisers boosted its stake in shares of BrainsWay by 10.8% during the 4th quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock worth $207,000 after acquiring an additional 2,144 shares during the last quarter. Good Life Advisors LLC raised its position in shares of BrainsWay by 65.5% during the 3rd quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock valued at $516,000 after purchasing an additional 22,080 shares during the period. Finally, Zuckerman Investment Group LLC raised its position in shares of BrainsWay by 346.4% during the 4th quarter. Zuckerman Investment Group LLC now owns 67,000 shares of the company’s stock valued at $667,000 after purchasing an additional 51,991 shares during the period. 30.11% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of BrainsWay in a report on Monday, December 23rd.

BrainsWay Stock Up 0.1 %

NASDAQ:BWAY traded up $0.01 during midday trading on Thursday, hitting $10.99. The company had a trading volume of 31,627 shares, compared to its average volume of 60,102. BrainsWay has a 52-week low of $4.61 and a 52-week high of $11.25. The stock’s fifty day moving average price is $9.98 and its 200-day moving average price is $9.19. The company has a market capitalization of $206.83 million, a PE ratio of 109.91 and a beta of 1.25.

BrainsWay (NASDAQ:BWAY) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03. BrainsWay had a net margin of 3.88% and a return on equity of 3.52%. The business had revenue of $10.50 million during the quarter, compared to analyst estimates of $10.07 million. During the same period in the prior year, the business posted ($0.01) earnings per share. As a group, research analysts forecast that BrainsWay will post 0.08 earnings per share for the current year.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.